# PDCD1

## Overview
The PDCD1 gene encodes the programmed cell death protein 1 (PD-1), a type I transmembrane receptor that plays a pivotal role in immune regulation. PD-1 is primarily expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells, where it functions as an immune checkpoint receptor. Upon engagement with its ligands, PD-L1 and PD-L2, PD-1 transmits inhibitory signals that attenuate immune cell activation, thereby maintaining immune homeostasis and preventing autoimmunity (Yokosuka2012Programmed; Francisco2010The). The PDCD1 gene is subject to alternative splicing, resulting in multiple isoforms that can modulate its function (Nielsen2005Alternative). Given its critical role in immune modulation, PD-1 is a significant target in cancer immunotherapy, where blockade of the PD-1 pathway can enhance anti-tumor immune responses (Xi2024AntiTumor). Additionally, genetic variations in PDCD1 are associated with susceptibility to autoimmune diseases and certain cancers, highlighting its clinical significance (Miao2020Prognostic; Fathi2019Effects).

## Structure
The PDCD1 gene encodes the programmed cell death protein 1 (PD-1), a type I transmembrane protein involved in immune regulation. The primary structure of PD-1 consists of 288 amino acids with a molecular weight of 31.6 kDa (Xi2024AntiTumor). The protein includes an extracellular immunoglobulin V-like domain, a transmembrane domain, and an intracellular domain containing immunoreceptor tyrosine-based inhibitory and switch motifs (ITIM and ITSM) (Xi2024AntiTumor; Nielsen2005Alternative).

Post-translational modifications of PD-1 are crucial for its function. These include ubiquitination at lysine residues K210 and K233, glycosylation at asparagine residues N49, N58, N74, and N116, phosphorylation at tyrosine residues Y223 and Y248, and palmitoylation at cysteine residue Cys192 (Xi2024AntiTumor). These modifications influence PD-1's stability, localization, and interactions with other proteins, such as SHP-2, which is recruited to phosphorylated tyrosine residues (Xi2024AntiTumor).

PDCD1 undergoes alternative splicing, resulting in several isoforms, including PD-1Δ3, which lacks the membrane-spanning domain and may be secreted as a soluble form (Sun2019Modulation). These splice variants can modulate PD-1's function and are expressed at varying levels depending on cellular activation (Nielsen2005Alternative).

## Function
The PDCD1 gene encodes the programmed cell death protein 1 (PD-1), a critical immune checkpoint receptor involved in regulating T cell activity. PD-1 is expressed on the surface of T cells, B cells, natural killer cells, monocytes, and dendritic cells, and its expression is inducible upon stimulation (Yokosuka2012Programmed). PD-1 functions as a negative costimulatory receptor, forming microclusters with T cell receptors (TCRs) upon binding to its ligands, PD-L1 and PD-L2. This interaction recruits the phosphatase SHP2, leading to the dephosphorylation of key signaling molecules downstream of the TCR, such as Vav1, PLCγ1, and Erk, thereby attenuating T cell activation (Yokosuka2012Programmed).

The PD-1 pathway is essential for maintaining immune homeostasis by controlling effector T-cell responses and preventing autoimmunity. It plays a role in the development and function of regulatory T cells (Tregs) and influences the fate of naive T cells upon antigen encounter (Francisco2010The). PD-1 is also involved in the conversion of naive T cells to Tregs, particularly in the presence of TGF-beta, which is crucial for maintaining immune tolerance (Francisco2010The). The PD-1 pathway's inhibitory effects are crucial for preventing overactivation of T cells, which can lead to autoimmune diseases (Yokosuka2012Programmed).

## Clinical Significance
Mutations and alterations in the PDCD1 gene, which encodes the PD-1 protein, have significant clinical implications. Variations in PDCD1 expression are associated with various cancers, as tumors can exploit the PD-1 pathway to evade immune detection. Elevated PDCD1 expression is observed in several cancer types, including breast invasive carcinoma, cholangiocarcinoma, and glioblastoma multiforme, while lower expression is noted in kidney chromophobe and thyroid carcinoma (Miao2020Prognostic). PDCD1 expression is linked to tumor mutational burden and microsatellite instability, which are important for the efficacy of immune checkpoint inhibitors (Miao2020Prognostic).

In autoimmune diseases, PDCD1 polymorphisms are associated with conditions like systemic lupus erythematosus (SLE). Specific SNPs, such as PD1.5, show significant associations with SLE susceptibility (Fathi2019Effects). PD-1 deficiency in mice leads to lupus-like autoimmune diseases, highlighting its role in maintaining self-tolerance (Nishimura1999Development).

In the context of non-alcoholic fatty liver disease (NAFLD), PDCD1 variants are linked to an increased risk of hepatocellular carcinoma (HCC), suggesting a role in cancer predisposition (Eldafashi2021A). These findings underscore the gene's importance in both cancer and autoimmune disease pathogenesis.

## Interactions
PDCD1, also known as PD-1, is a critical immune checkpoint protein that interacts with various ligands and intracellular proteins to modulate immune responses. PD-1 primarily interacts with its ligands PD-L1 and PD-L2, which are expressed on antigen-presenting cells (APCs). These interactions inhibit T cell activation, proliferation, and cytokine production, contributing to immune tolerance (Sugiura2019Restriction; Li2017In).

PD-1 contains two tyrosine motifs, ITIM and ITSM, which are phosphorylated upon ligand engagement. This phosphorylation recruits SHP-2 and SHP-1 phosphatases, which inhibit T cell activation by targeting downstream signaling pathways of the T cell receptor (TCR) and CD28 (CelisGutierrez2019Quantitative; Wang2021The). SHP-2 is the predominant phosphatase recruited by PD-1, but SHP-1 can substitute for SHP-2 in its absence, maintaining PD-1's inhibitory function (CelisGutierrez2019Quantitative).

PD-1 also forms complexes with other proteins, such as GRB2 and ZAP70, which are involved in T cell signaling (CelisGutierrez2019Quantitative). Additionally, PD-1 interacts with FBXO38, which mediates its degradation through poly-ubiquitination (Wang2021The). These interactions highlight PD-1's role in modulating immune responses and its potential as a therapeutic target in cancer and autoimmune diseases.


## References


[1. (Xi2024AntiTumor) Xiaoming Xi and Wuli Zhao. Anti-tumor potential of post-translational modifications of pd-1. Current Issues in Molecular Biology, 46(3):2119–2132, March 2024. URL: http://dx.doi.org/10.3390/cimb46030136, doi:10.3390/cimb46030136. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cimb46030136)

[2. (Francisco2010The) Loise M. Francisco, Peter T. Sage, and Arlene H. Sharpe. The pd‐1 pathway in tolerance and autoimmunity. Immunological Reviews, 236(1):219–242, June 2010. URL: http://dx.doi.org/10.1111/j.1600-065x.2010.00923.x, doi:10.1111/j.1600-065x.2010.00923.x. This article has 1734 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/j.1600-065x.2010.00923.x)

[3. (Nishimura1999Development) Hiroyuki Nishimura, Masato Nose, Hiroshi Hiai, Nagahiro Minato, and Tasuku Honjo. Development of lupus-like autoimmune diseases by disruption of the pd-1 gene encoding an itim motif-carrying immunoreceptor. Immunity, 11(2):141–151, August 1999. URL: http://dx.doi.org/10.1016/s1074-7613(00)80089-8, doi:10.1016/s1074-7613(00)80089-8. This article has 2054 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1074-7613(00)80089-8)

[4. (Wang2021The) Qi Wang, Kankana Bardhan, Vassiliki A. Boussiotis, and Nikolaos Patsoukis. The pd‐1 interactome. Advanced Biology, June 2021. URL: http://dx.doi.org/10.1002/adbi.202100758, doi:10.1002/adbi.202100758. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/adbi.202100758)

[5. (Sun2019Modulation) Junjie Sun, Jialin Bai, Tao Jiang, Yuan Gao, and Yimin Hua. Modulation of pdcd1 exon 3 splicing. RNA Biology, 16(12):1794–1805, August 2019. URL: http://dx.doi.org/10.1080/15476286.2019.1659080, doi:10.1080/15476286.2019.1659080. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/15476286.2019.1659080)

[6. (Yokosuka2012Programmed) Tadashi Yokosuka, Masako Takamatsu, Wakana Kobayashi-Imanishi, Akiko Hashimoto-Tane, Miyuki Azuma, and Takashi Saito. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit t cell receptor signaling by recruiting phosphatase shp2. Journal of Experimental Medicine, 209(6):1201–1217, May 2012. URL: http://dx.doi.org/10.1084/jem.20112741, doi:10.1084/jem.20112741. This article has 867 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1084/jem.20112741)

[7. (CelisGutierrez2019Quantitative) Javier Celis-Gutierrez, Peter Blattmann, Yunhao Zhai, Nicolas Jarmuzynski, Kilian Ruminski, Claude Grégoire, Youcef Ounoughene, Frédéric Fiore, Ruedi Aebersold, Romain Roncagalli, Matthias Gstaiger, and Bernard Malissen. Quantitative interactomics in primary t cells provides a rationale for concomitant pd-1 and btla coinhibitor blockade in cancer immunotherapy. Cell Reports, 27(11):3315-3330.e7, June 2019. URL: http://dx.doi.org/10.1016/j.celrep.2019.05.041, doi:10.1016/j.celrep.2019.05.041. This article has 109 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2019.05.041)

[8. (Nielsen2005Alternative) Christian Nielsen, Line Ohm-Laursen, Torben Barington, Steffen Husby, and Søren T. Lillevang. Alternative splice variants of the human pd-1 gene. Cellular Immunology, 235(2):109–116, June 2005. URL: http://dx.doi.org/10.1016/j.cellimm.2005.07.007, doi:10.1016/j.cellimm.2005.07.007. This article has 174 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellimm.2005.07.007)

[9. (Eldafashi2021A) Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, Misti Vanette McCain, Robyn Watson, Yang Lin Liu, Nikki McStraw, Moustafa Fathy, Michael Atef Fawzy, Marco Y. W. Zaki, Ann K. Daly, João P. Maurício, Alastair D. Burt, Beate Haugk, Heather J. Cordell, Cristiana Bianco, Jean-François Dufour, Luca Valenti, Quentin M. Anstee, and Helen L. Reeves. A pdcd1 role in the genetic predisposition to nafld-hcc? Cancers, 13(6):1412, March 2021. URL: http://dx.doi.org/10.3390/cancers13061412, doi:10.3390/cancers13061412. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13061412)

[10. (Li2017In) Kaitao Li, Xiaoxiao Cheng, Andreas Tilevik, Simon J. Davis, and Cheng Zhu. In situ and in silico kinetic analyses of programmed cell death-1 (pd-1) receptor, programmed cell death ligands, and b7-1 protein interaction network. Journal of Biological Chemistry, 292(16):6799–6809, April 2017. URL: http://dx.doi.org/10.1074/jbc.m116.763888, doi:10.1074/jbc.m116.763888. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m116.763888)

[11. (Sugiura2019Restriction) Daisuke Sugiura, Takumi Maruhashi, Il-mi Okazaki, Kenji Shimizu, Takeo K. Maeda, Tatsuya Takemoto, and Taku Okazaki. Restriction of pd-1 function by cis -pd-l1/cd80 interactions is required for optimal t cell responses. Science, 364(6440):558–566, May 2019. URL: http://dx.doi.org/10.1126/science.aav7062, doi:10.1126/science.aav7062. This article has 274 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.aav7062)

[12. (Miao2020Prognostic) Yandong Miao, Jiangtao Wang, Qiutian Li, Wuxia Quan, Yingying Wang, Chen Li, Jingjing Wu, and Denghai Mi. Prognostic value and immunological role of pdcd1 gene in pan-cancer. International Immunopharmacology, 89:107080, December 2020. URL: http://dx.doi.org/10.1016/j.intimp.2020.107080, doi:10.1016/j.intimp.2020.107080. This article has 58 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.intimp.2020.107080)

[13. (Fathi2019Effects) Farshid Fathi, Erfan Sadeghi, Noushin Lotfi, Hossein Hafezi, Meysam Ahmadi, Samaneh Mozafarpoor, and Hossein Motedayyen. Effects of the programmed cell death 1 (pdcd1) polymorphisms in susceptibility to systemic lupus erythematosus. International Journal of Immunogenetics, 47(1):57–64, September 2019. URL: http://dx.doi.org/10.1111/iji.12456, doi:10.1111/iji.12456. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/iji.12456)